Search hospitals
>
Illinois
>
Peru
Illinois CancerCare-Peru
Claim this profile
Peru, Illinois 61354
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Breast cancer
Conducts research for Non-Small Cell Lung Cancer
385 reported clinical trials
2 medical researchers
Summary
Illinois CancerCare-Peru is a medical facility located in Peru, Illinois. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Peru is involved with conducting 385 clinical trials across 474 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.
Area of expertise
Breast Cancer
Illinois CancerCare-Peru has run 69 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Illinois CancerCare-Peru has run 68 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Bryan A. Faller
Crossroads Cancer Center
7 years of reported clinical research
James L. Wade
Decatur Memorial Hospital
4 years of reported clinical research
Clinical Trials running at Illinois CancerCare-Peru
Lung Cancer
Prostate Cancer
Breast Cancer
Cancer
Pancreatic Cancer
Breast cancer
Bladder Cancer
Colorectal Cancer
Ovarian Cancer
Esophageal cancer
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting
2 awards
Phase 3
4 criteria
Ceralasertib + Durvalumab
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
Recruiting
2 awards
Phase 3
10 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Illinois CancerCare-Peru?
Illinois CancerCare-Peru is a medical facility located in Peru, Illinois. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Peru is involved with conducting 385 clinical trials across 474 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.
Where is Illinois CancerCare-Peru located?
**Illinois CancerCare - Peru Location** - **Address:** 4391 Venture Dr, Suite 1, Peru, IL 61354 - **Part of:** Valley Regional Cancer Center - **Contact:** For more information, visit their website or call (815) 223-7010.
Who should I call to ask about financial aid or insurance network?
For inquiries about financial assistance and insurance matters at Illinois CancerCare-Peru, please contact the main line at (217) 383-3311. The Illinois CancerCare Foundation also provides financial assistance for tumor sequencing and targeted oral therapies for eligible patients.
What insurance does Illinois CancerCare-Peru accept?
Illinois CancerCare-Peru accepts a wide range of insurance plans, including but not limited to Medicare, Aetna (HMO, PPO, POS), BCBS of Illinois (PPO, POS, EPO, Classic Blue HMO, HMOI, Blue Advantage HMO), Beech Street PPO, Cigna/Great West Healthcare (HMO, PPO, POS, Open Access), and United Health Care. It is crucial to confirm that your physicians are within your plan's network. Additionally, pre-certification may be required for those in an HMO or PPO plan.
What awards or recognition has Illinois CancerCare-Peru received?
Illinois CancerCare-Peru, located in Peru, Illinois, is nationally recognized for its excellence in clinical research, being one of the top enrollers for the Alliance for Clinical Trials in Oncology in 2015. Additionally, it has earned certification from the Quality Oncology Practice Initiative (QOPI®) for meeting stringent national standards in cancer care.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.